Free Trial

Bio-Path (BPTH) Competitors

Bio-Path logo
$0.16 0.00 (-1.90%)
As of 07/24/2025 03:54 PM Eastern

BPTH vs. ENSC, QLGN, SPRB, VIVS, MTNB, ORGS, GLTO, ADIL, GRI, and REVB

Should you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include Ensysce Biosciences (ENSC), Qualigen Therapeutics (QLGN), Spruce Biosciences (SPRB), VivoSim Labs (VIVS), Matinas Biopharma (MTNB), Orgenesis (ORGS), Galecto (GLTO), Adial Pharmaceuticals (ADIL), GRI Bio (GRI), and Revelation Biosciences (REVB). These companies are all part of the "pharmaceutical products" industry.

Bio-Path vs. Its Competitors

Bio-Path (NASDAQ:BPTH) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Bio-Path has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Ensysce Biosciences has higher revenue and earnings than Bio-Path.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08MN/AN/A
Ensysce Biosciences$5.21M1.00-$7.99M-$6.54-0.34

Bio-Path has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -109.49%. Ensysce Biosciences' return on equity of -192.54% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
Ensysce Biosciences -109.49%-192.54%-121.77%

In the previous week, Ensysce Biosciences had 1 more articles in the media than Bio-Path. MarketBeat recorded 1 mentions for Ensysce Biosciences and 0 mentions for Bio-Path. Ensysce Biosciences' average media sentiment score of 1.89 beat Bio-Path's score of 0.00 indicating that Ensysce Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Path Neutral
Ensysce Biosciences Very Positive

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 7.9% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Ensysce Biosciences beats Bio-Path on 8 of the 10 factors compared between the two stocks.

Get Bio-Path News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPTH vs. The Competition

MetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.31M$815.90M$5.72B$9.47B
Dividend YieldN/A4.84%4.60%3.99%
P/E RatioN/A1.3827.9419.95
Price / SalesN/A26.59452.94100.82
Price / CashN/A19.5636.5558.97
Price / Book0.226.818.645.90
Net Income-$16.08M-$4.28M$3.24B$258.42M
7 Day Performance-0.64%1.60%3.69%2.11%
1 Month Performance-11.43%4.40%10.33%12.44%
1 Year Performance-91.14%9.12%34.30%19.55%

Bio-Path Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPTH
Bio-Path
0.9665 of 5 stars
$0.16
-1.9%
N/A-91.0%$1.31MN/A0.0010
ENSC
Ensysce Biosciences
1.0237 of 5 stars
$2.17
+1.9%
N/A-63.2%$5.05M$5.21M-0.3310
QLGN
Qualigen Therapeutics
N/A$3.07
+2.0%
N/A-74.5%$4.92M$4.98M0.0050Earnings Report
Gap Down
SPRB
Spruce Biosciences
2.2041 of 5 stars
$0.12
+5.7%
$1.75
+1,404.7%
-77.5%$4.91M$4.91M-0.1220News Coverage
Stock Split
Gap Down
VIVS
VivoSim Labs
N/A$1.98
+4.8%
N/AN/A$4.91M$140K-0.1920
MTNB
Matinas Biopharma
N/A$0.95
-0.6%
N/AN/A$4.85MN/A-0.2030Gap Down
ORGS
Orgenesis
1.8698 of 5 stars
$1.01
-2.9%
N/AN/A$4.85M$662K0.00150Gap Up
GLTO
Galecto
3.7617 of 5 stars
$3.60
+0.3%
$10.00
+177.8%
-72.3%$4.74MN/A-0.2340
ADIL
Adial Pharmaceuticals
2.9655 of 5 stars
$0.51
+12.4%
$8.00
+1,477.9%
-59.6%$4.71MN/A-0.3520
GRI
GRI Bio
2.4351 of 5 stars
$1.99
+9.3%
$22.00
+1,005.5%
-91.4%$4.54MN/A-0.171Positive News
Gap Up
REVB
Revelation Biosciences
1.7629 of 5 stars
$3.06
+3.7%
N/A-96.2%$4.53MN/A-0.0110High Trading Volume

Related Companies and Tools


This page (NASDAQ:BPTH) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners